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M A J O R A R T I C L E
NeuronalQ1 Bioenergetics and Acute Mitochondrial
Dysfunction: A Clue to Understanding the
Central Nervous System Side Effects of Efavirenz
Haryes A. Funes,1,3,a Nadezda Apostolova,4,5,a Fernando Alegre,1,3 Ana Blas-Garcia,1,3 Angeles Alvarez,1,2,4
5 Miguel Marti-Cabrera,1,4 and Juan V.Q2 Esplugues1,3,4
1Departamento de Farmacología, Facultad de Medicina, and 2Fundación General, Universidad de Valencia, 3FISABIO–Hospital Universitario Dr. Peset, and
4CIBERehd, Valencia, and 5Facultad de Ciencias de la Salud, Universidad Jaime I, Castellón de la Plana, Spain
Background. Neurological pathogenesis is associated with mitochondrial dysfunction and differences in
neuronal/glial handling of oxygen and glucose. The main side effects attributed to efavirenz involve the CNS,
10 but the underlying mechanisms are unclear.
Methods. Human cell lines and rat primary cultures of neurons and astrocytes were treated with clinically rel-
evant efavirenz concentration.
Results. Efavirenz alters mitochondrial respiration, enhances reactive oxygen species generation, undermines
mitochondrial membrane potential, and reduces adenosine triphosphate (ATP) levels in a concentration-dependent
15 fashion in both neurons and glia. HoweverQ4 , it triggers adenosine monophosphate–activated protein kinase only in
glia, upregulating glycolysis and increasing intracellular ATP levels, which do not occur in neurons. To reproduce the
conditions that often exist in human immunodeﬁciency virus–related neuroinﬂammatory disorders, the effects of
efavirenz were evaluated in the presence of exogenous nitric oxide, an inﬂammatory mediator and mitochondrial
inhibitor. The combination potentiated the effects on mitochondrial parameters in both neurons and glia, but
20 ATP generation and lactate production were enhanced only in glia.
Conclusions. Efavirenz affects the bioenergetics of neurons through a mechanism involving acute mitochondrial
inhibition, an action exacerbated in neuroinﬂammatory conditions. A similar scenario of glia survival and degener-
ation of neurons with signs of mitochondrial dysfunction and oxidative stress has been associated with neurocog-
nitive disorders.
25 Keywords. Mitochondria; neurotoxicity; HIV; nitric oxide; central nervous system; efavirenz; HIV-associated
neurocognitive disorders.
30 There is growing evidence that neurological pathogen-
esis is often linked to mitochondrial dysfunction and
the way neurons and glia handle oxygen/glucose. It
has been shown that astrocytes are protected from
mitochondrial inhibition by the rapid upregulation
35of adenosine monophosphate (AMP)–activated protein
kinase (AMPK)–mediated glycolysis. Neurons, on the
other hand, lack this defense mechanism and are there-
fore more vulnerable [1, 2]. This action is relevant given
that several neurodegenerative diseases, including
40human immunodeﬁciency virus (HIV)–associated neu-
rocognitive disorders, are characterized by the selective
damage of neurons versus glial cell survival [3]. In this
context, the aforementioned action could also underlie
drug-induced brain toxicity.
45The nonnucleoside reverse transcriptase inhibi-
tor (NNRTI) efavirenz (EFV) is a widely prescribed
anti-HIV drug. However, many patients exhibit central
nervous system (CNS)–related side effects, including diz-
ziness, a hangover-like sensation, impaired concentration,
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50 nervousness, sleep disturbances, psychosis, suicidal ideation,
and neurocognitive impairment. In some cases, these effects
are so severe that the therapy requires discontinuation [4–6].
The mechanism of toxicity in the CNS is yet to be determined,
although certain evidence implicates mitochondria. For exam-
55 ple, EFV has been shown to affect mitochondrial oxidative
phosphorylation in the mouse brain [7]. In hepatic cells, this
drug undermined mitochondrial function, leading to the activa-
tion of AMPK, the master switch of cellular bioenergetics. Such
a response was compound speciﬁc, as it was not reproduced by
60 nevirapine, another widely prescribed NNRTI, and was unrelat-
ed to the interference of mitochondrial DNA replication com-
monly associated with other anti-HIV drugs [8, 9].
In light of this evidence, we analyzed the actions of EFV in
neurons and glia, the possible interference with mitochondria,
65 and the effect on glycolysis. In addition, since HIV infection is
often accompanied by neuroinﬂammation [10], we evaluated
the way nitric oxide (NO), a well-known mediator of inﬂamma-
tion and inhibitor of mitochondrial function, affects the afore-
mentioned actions of EFV.
70 MATERIALS AND METHODS
Reagents and Treatments
Unless otherwise stated, chemicals were from Sigma-Aldrich
(Steinheim, Germany). EFV (Sequoia Research Products,
Pangbourne, United Kingdom) was dissolved in methanol
75 (3 mg/mL). Methanol 0.25%, which did not have a signiﬁcant
impact on any of the parameters studied, was used for all
EFV treatments and vehicle control experiments, and statistical
analyses of differences between ﬁndings of these tests was per-
formed. In the experiments with exogenous NO, cells were
80 treated with 0.3-mM (for neurons) or 0.5-mM (for glia) con-
centrations of DETA-NO ((Z)-1-[2-aminoethyl)-N-(2-ammo-
nioethyl)amino]diazen-1-ium-1,2-diolate; Alexis, San Diego,
CA), which are capable of inhibiting cellular respiration [11].
Immediate NO exposure was ensured by preheating (at 37°C
85 for 20 minutes) the freshly prepared DETA-NO/Milli-Q water
solution before application. For the cotreatments, DETA-NO
was added 1 hour before EFV administration.
Cell Culture
Unless stated otherwise, reagents were from Gibco (Invitrogen,
90 Eugene, OR). Cell cultures were maintained in an incubator
(IGO 150, Jouan, Saint-Herblain Cedes, France) at 37°C in a
humidiﬁed atmosphere of 5% CO2 and 95% air (AirLiquide
Medicinal, Valencia, Spain). Experiments were performed
with subconﬂuent cultures in complete medium supplemented
95 with 3% (v/v) heat-inactivated fetal bovine serum (FBS). The
human glioma cell line U-251MG (CLS 300385) was cultured
in Dulbecco’s modiﬁed Eagle’s medium (DMEM; Sigma-
Aldrich), and the human neuroblastoma cell line SH-SY5Y
(ATCC CRL-2266) was cultured in Roswell Park Memorial In-
100stitute 1640 medium supplemented with 2.383 g/L HEPES, 1.5
g/L sodium bicarbonate, and 110 mg/L sodium pyruvate. Both
media contained 4.5 g/L glucose and were supplemented with
10% FBS, 1 mM NEAA, 2 mM L-glutamine, penicillin (50
units/mL), and streptomycin (50 µg/mL). SH-SY5Y cells were
105differentiated into neurons prior to treatment. A 1-mM concen-
tration of db-cAMP (N(6),2′-O-dibutyryladenosine 3′:5′ cyclic
monophosphate) [12] was added 1 day after seeding, and cells
were then allowed to differentiate for 6 days, with medium re-
placed every 48 hours.
110Primary cultures of astrocytes and neurons were obtained from
rat cerebral cortex [13]. In brief, astrocytes from neonatal (24-
hours-old) Wistar rats were seeded (1.2 × 105 cells/cm2 in 150-
cm2 ﬂasks) in DMEM supplemented with 10% FBS and cultured
for 12–14 days. Under these conditions, astrocytes represented
11585% of the cells, the remaining proportion being microglia and
progenitor cells. Primary cultures of neurons were prepared
from rat fetuses at gestation day 15, cell suspensions were plated
(2.5 × 105 cells/cm2 in plates or ﬂasks previously coated with 15
µg/mL poly-D-lysine) in DMEM supplemented with 10% FBS; 48
120hours later the medium was replaced with DMEM supplemented
with 5% horse serum, 20 mMD-glucose, and 10 µM cytosine ara-
binoside (to prevent nonneuronal proliferation). Neurons were
used on day 7, when the presence of neuroﬁlaments was evident
in 99% of the cells. The protocols regarding isolation and primary
125cell culture complied with European Community guidelines for
the use of animal experimental models and were approved by
the Ethics Committee of the University of Valencia.
Cell Viability
Cell viability was studied by the colorimetric MTT [3-(4,5-di-
130methylthiazol-2-yl)-2,5-diprenyl tetrazolium bromide] assay.
U-251MG cells (2 × 104 cells/cm2), SH-SY5Y (1.5 × 104 cells/
cm2), primary neurons (2.5 × 105 cells/cm2), and astrocytes
(2 × 104 cells/cm2) were allowed to attach in 96-well plates.
MTT reagent (Roche Diagnostics, Mannheim, Germany) was
135added (20 µL/well) during last 4 hours of the 24-hour treatment
period; cells were then dissolved in DMSO (100 µL/well) for 5
minutes at 37°C, and absorbance was measured by a Multiskan
plate-reader spectrophotometer (Thermo Labsystems, Thermo
Scientiﬁc, Rockford, IL).
140Fluorescence Microscopy and Static Cytometry
The signal was detected (Olympus IX81 microscope) and
quantiﬁed using ScanR static cytometry software, version
2.03.2 (Olympus, Hamburg, Germany). U-251MG (3 × 104
cells/cm2), SH-SY5Y (1.5 × 104 cells/cm2), primary neurons
145(2.5 × 105/cm2), and astrocytes (4 × 104 cells/cm2) were treated
in duplicate in 48-well plates and washed in Hank’s balanced
salt solution (HBSS), and 16–20 life-cell images/well were im-
mediately recorded.
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Cell Proliferation and Survival
150 Cells proliferated exponentially for 24 hours in the presence of
vehicle, EFV, DETA-NO, or EFV + DETA-NO and then were
counted according to Hoechst ﬂuorescence (1 µM Hoechst
33 342; 25 images/well).
Mitochondrial Superoxide Production and Mitochondrial
155 Membrane Potential (Δψm)
Cells were treated for 6 hours and/or 24 hours in vehicle, EFV,
DETA-NO, or EFV + DETA-NO, and ﬂuorochromes, 1 µM
Hoechst 33 342, and either 2.5 µM MitoSOX (for superoxide
analysis) or 2.5 µM TMRM (for Δψm analysis; Molecular
160 Probes, Invitrogen, Eugene, OR) were added for the last 30 min-
utes of treatment. Rotenone 10 µM (a widely used inhibitor of
mitocondrial complex I) and FCCP 10 µM (a pharmacological
uncoupler of mitochondrial oxidative phosphorylation) were
used as positive controls for analyses of superoxide production
165 and Δψm, respectively.
Metabolite Determinations
The level of intracellular adenosine triphosphate (ATP) was de-
termined in cells incubated for 24 hours (with EFV, DETA-NO,
or DETA-NO + EFV) by the ATP Bioluminescence Assay Kit
170 HSII (Roche Diagnostics) and a Fluoroskan microplate reader
(Thermo Labsystems). The lactate concentration in the extracel-
lular medium was evaluated in 96-well plates, using the Lactate
Assay Kit (BioVision, San Francisco, CA) and a Multiskan plate
reader spectrophotometer (Thermo Labsystems). For both me-
175 tabolites, protein concentrations were determined using the
BCA protein assay kit (Pierce Chemicals, Boulder, CO).
Electrochemical Measurement of Oxygen (O2) Consumption
Cells (5 × 106 per 1 mL of HBSS) were agitated in a gas-tight
chamber at 37°C. Measurements were taken with a Clark-type
180 O2 electrode (Rank Brothers, Bottisham, United Kingdom) and
recorded with the Duo.18 data acquisition device (WPI, Steven-
age, United Kingdom) immediately after addition of EFV
(10–25 µM), DETA-NO, or the respective solvents.
Protein Extract Isolation and Western Blotting
185 Total protein extracts of cells treated for 6 hours were isolated,
and immunoblotting was performed as described previously
[8]. In brief, cell pellets were lysed in PhosphoSafe lysis buffer
(Novagen, Calbiochem, La Jolla, CA) supplemented with prote-
ase inhibitors (Complete Mini protease inhibitor cocktail,
190 Roche Diagnostics) to ensure preservation of the phosphorylat-
ed form of AMPK. In some experiments, the AMPK inhibitor
compound C (6-[4-(2-Piperidin-1-ylethoxy)-phenyl)]-3-pyri-
din-4-ylpyrazolo[1,5-a]pyrimidine, Calbiochem, La Jolla, CA)
was added 30 minutes before EFV administration and through-
195 out the 6- or 24-hour incubation period. Samples were vortexed,
incubated for 5 minutes, vortexed a second time, and centri-
fuged at 16 100 ×g for 5 minutes at 4°C. The total protein
concentration was quantiﬁed by the BCA protein assay kit
(Pierce Chemicals), and equal amounts of protein (40 µg)
200were loaded onto sodium dodecyl sulfate polyacrylamide gels
and analyzed by Western blotting (BioRad, Hercules, CA),
using anti-AMPK alpha 1 + alpha 2 (phospho T172) polyclonal
antibody (1:1000, Abcam, Cambridge, United Kingdom) or
anti-actin (1:1000 [primary antibody]; Sigma-Aldrich; primary
205antibody) and peroxidase-labeled anti-rabbit IgG (1:5000 [sec-
ondary antibody]; Vector laboratories, Burlingame, CA). Pro-
tein bands were detected by a LAS-3000 digital luminescent
image analyzer (Fujiﬁlm), using the enhanced chemilumines-
cent reagent ECL (Amersham, GE Healthcare, Little Chalfont,
210United Kingdom) or SuperSignal WestFemto (Pierce Chemi-
cals). Protein expression was quantiﬁed by means of densitom-
etry (Image Gauge software, version 4.0, Fujiﬁlm). Data were
normalized to values for actin, and results are expressed as
the percentage induction relative to the control group.
215Presentation of Data and Statistical Analysis
Data were analyzed by means of the Student t test (GraphPad
Prism software, version 5). All values are mean ± standard error
of the mean, and statistical signiﬁcance was deﬁned as a P value
of <.05. In most cases, data are represented as the percentage of
220the value for the negative control, with the negative control
(untreated cells) considered 100%.
RESULTS
EFV Disrupts Mitochondrial Function and
Compromises Cell Viability
225Acute EFV treatment (10 µM and 25 µM) diminished O2 con-
sumption rapidly and in a concentration-dependent manner in
SH-SY5Y (neurons) and U-251MG (glia; Figure 1 Q5A). In addi-
tion, 2 parameters of mitochondrial function were affected Q6in
both cell populations (6 and 24 hours). First, ﬂuorescence mi-
230croscopy revealed a signiﬁcant and concentration/time-depen-
dent increase in superoxide production (Figure 1B). Second,
EFV produced a major reduction in Δψm that was slightly
more pronounced in glia than in neurons (Figure 1C). Addi-
tionally, cell viability/proliferation in SH-SY5Y was reduced in
235a concentration-dependent manner following 24 hours of incu-
bation, an effect not observed in U-251MG (Figure 1D). The re-
sults obtained in neuroblastoma and glioma cell lines were
reproduced in primary cultures of rat neurons and astrocytes
(Figure 2). Thus, an increase in mitochondrial superoxide gen-
240eration and a decrease in Δψm (Figure 2A and 2B, respectively)
were observed in both cell populations after 24 hours of treat-
ment. Moreover, the viability of neurons was substantially com-
promised by EFV, while that of astrocytes was only slightly
affected by the higher concentration of EFV (Figure 2C).
245These data show that the deleterious action of EFV on mito-
chondrial function previously reported in hepatocytes is also
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Figure 1. Effect Q9of efavirenz (EFV) on mitochondrial function in SH-SY5Y (neuroblastoma cells) and U-251MG (glioma cells). A, Efavirenz acutely de-
creases O2 consumption. Representative traces and quantiﬁcation of data showing the rate of O2 consumption (Clark-type O2 electrode) in the absence
(vehicle; Veh) and presence of EFV 10 µM and 25 µM. B and C,
Q10
Determination of superoxide production, expressed as relative MitoSOX ﬂuorescence (B),
and mitochondrial membrane potential, expressed as relative TMRM ﬂuorescence (C), in cells treated with increasing concentrations of EFV or vehicle for 6
and 24 hours, using rotenone (ROT) and FCCP (both at 10 µM) as positive controls, respectively. D, Effect of EFV (24 hours) on cell viability according to the
MTT assay; results represent relative absorbance (λ = 570 nm) and are expressed as the percentage of the absorbance recorded in untreated cells. Data
(mean ± standard error of the mean; n = 3–5) were compared with those of untreated cells (the values for which were considered 100%) and analyzed by the
Student t test. *P < .05, **P < .01, and ***P < .001, compared with vehicle; #P < .05, ##P < .01, and ###P < .001, for comparisons of ROT and FCCP values to
those for untreated cells.
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produced in neurons and glial cells and provide the ﬁrst evi-
dence that neurons are more susceptible than glia to the nega-
tive effects of this drug on cell viability.
250EFV Affects the Bioenergetics of Neurons and Glial
Cells in Different Ways
Having conﬁrmed that EFV compromises mitochondrial func-
tion, we next explored its effect on cellular bioenergetics. Inhi-
bition of mitochondrial respiration is known to activate AMPK,
255a major sensor of cell energetic stress [14]. We observed
that EFV (6 hours) induced a signiﬁcant and concentration-
dependent increase in AMPK phosphorylation in glia but not
in neurons (Figure 3A). Longer incubation (24 hours) induced
a signiﬁcant and concentration-dependent increase in ATP
260levels in the former cells but not in the latter (Figure 3B). The
lactate level in the extracellular medium, an indicator of glycol-
ysis activation, was determined to clarify whether the augment-
ed ATP concentration in glial cells was the result of enhanced
glycolysis. We found a major, concentration-dependent in-
265crease in lactate generation in glia (Figure 3C), an effect that
was absent when a glucose-free or galactose-containing medi-
um was used (Supplementary Figure 1), thus pointing to en-
hanced glycolysis. Once again, these effects were not observed
in neurons. Coincubation (for 6 or 24 hours) of glia with com-
270pound C, an inhibitor of AMPK, blocked the activation of gly-
colysis (Figure 3D). These ﬁndings were reproduced in primary
cultures, where enhanced ATP (Figure 3E ) and lactate (Fig-
ure 3F) levels were observed in astrocytes but not in neurons.
Considered together, these results demonstrate that glycolysis
275is triggered as a result of the following sequence of events: mi-
tochondrial inhibition, intracellular ATP reduction, and AMPK
activation.
Effect of EFV Is Exacerbated in the Presence
of a Proinﬂammatory Stimulus
280To analyze whether a proinﬂammatory state in the brain exac-
erbates the effects of EFV on mitochondria, exogenous NO was
added to the cell culture. As expected, DETA-NO undermined
mitochondrial respiration in both neuronal and glial cell lines.
This action was enhanced in the presence of EFV (10 µM; Fig-
285ure 4A). EFV + DETA-NO also had an additive effect on the
other 2 parameters of mitochondrial function assessed: super-
oxide production (Figure 4B) and Δψm (Figure 4C). DETA-NO
alone produced an increase in mitochondrial superoxide in
both SH-SY5Y and U-251MG. In accordance with previous re-
290ports [11],Δψm was diminished in neurons and increased in glia
in the presence of DETA-NO alone, whereas EFV reduced this
parameter in both cell populations, an effect that was more
pronounced when DETA-NO was present. Regarding the acti-
vation of glycolysis, DETA-NO elicited an increase in intracel-
295lular ATP in the neuroblastoma, with no changes in the glioma
cells; however, increased lactate generation was detected in both.
Notably, the glycolytic effect of EFV exhibited only by the gli-
oma cells was strengthened in the presence of exogenous NO, as
displayed by the ATP level (Figure 4D) and lactate release
300(Figure 4E).
Figure 2. Effect of efavirenz (EFV; 24 hours) on mitochondrial parame-
ters in primary cultures of rat cortical neurons and astrocytes. A and B,
Determination of superoxide production, expressed as relative MitoSOX
ﬂuorescence (A), and mitochondrial membrane potential, shown as relative
TMRM ﬂuorescence (B), with increasing concentrations of EFV or vehicle
(Veh), using rotenone (ROT) and FCCP (both at 10 µM), respectively, as pos-
itive controls. C, Effect of EFV on cell viability as measured by the MTT
assay; results represent relative absorbance (λ = 570 nm) and are ex-
pressed as the percentage of the absorbance recorded in untreated
cells. Data (mean ± standard error of the mean; n = 4–5) were compared
to those of untreated cells (the values for which were considered 100%)
and analyzed by the Student t test. *P < .05, **P < .01, and ***P < .001,
compared with vehicle; ##P < .01 and ###P < .001 for comparisons of ROT
and FCCP values to those for untreated cells.
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Figure 3. Efavirenz (EFV) produces a differential effect on cell bioenergetics in neurons and glia. A, SH-SY5Y (neuroblastoma cells) and U-251MG (glioma
cells) were assessed for protein expression (Western blot) of phosphorylated AMPK (P-AMPK) in cells incubated without (vehicle; Veh) or with EFV for 6
hours. Representative images and histograms of the densitometric scans for the P-AMPK protein band, normalized with those of β-actin, are provided.
Results show protein expression in relation to that of untreated cells in each individual experiment (considered 100%). B, Intracellular ATP levels were
assessed in SH-SY5Y and U-251MG 24 hours after EFV treatment. C, Determination of the lactate level in the extracellular medium in cells treated with EFV
for 24 hours. D, Determination of the lactate level in the extracellular medium of U-251MG cotreated with the AMPK inhibitor compound C (Cc) for 6 hours
(left) and 24 hours (right). E and F, Primary cultures of neurons and astrocytes treated with vehicle or EFV for 24 hours were assessed for intracellular ATP
levels (E ) and lactate production (F ) in the extracellular medium. Data (mean ± standard error of the mean; n = 4–5 except for panel D [n = 3]) were compared
to those for untreated cells (the values for which were considered 100%) and analyzed by the Student t test. *P < .05, **P < .01, ***P < .001, compared with
vehicle; ++P < .01 for comparison of EFV10 to EFV10 + Cc; ^^P < .01 for comparison of EFV25 to EFV25 + Cc.
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Figure 4. Effect of efavirenz (EFV) on SH-SY5Y (neuroblastoma cells) and U-251MG (glioma cells) in the presence of exogenous nitric oxide (NO). His-
tograms represent data obtained in the absence (vehicle; Veh) and presence of EFV 10 µM or DETA-NO (0.3 mM in neurons and 0.5 mM in glial cells) or
cotreatment with DETA-NO + EFV 10 µM. A, O2 consumption in intact cells of SH-SY5Y and U-251MG. B–F, At 24 hours, the effect of the combined treat-
ment was evaluated according to the following parameters: mitochondrial redox state, in terms of superoxide production (B) and mitochondrial membrane
potential (C); intracellular ATP level (D), lactate production (E ), and cell number (F ). Histograms represent cell count, determined by static cytometry (Hoechst
ﬂuorescence). Data (mean ± standard error of the mean; n = 3–5 were expressed as the percentage of the value for untreated cells (which was considered to
be 100%) and analyzed by the Student t test. *P < .05, **P < .01, and ***P < .001, compared with vehicle; ^P < .05, ^^P < .01, and ^^^P < .001 for com-
parisons of EFV 10 µM to DETA-NO + EFV 10 µM);+P < .05 and +++P < .001 for comparisons of DETA-NO to cotreatment of DETA-NO + EFV 10 µM.
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Finally, we aimed to evaluate whether this additive action of
DETA-NO and EFV had consequences for the cell number and
viability (Figure 4F ). DETA-NO depleted the number of
neuroblastoma and glioma cells, with the previous cells being
305more susceptible. EFV (10 µM) alone provoked only a slight re-
duction in the number of SH-SY5Y, an effect that was enhanced
when these cells were cotreated with exogenous NO. Important-
ly, in U-251MG, the combined treatment did not aggravate the
effect of DETA-NO. These ﬁndings are relevant for further un-
310derstanding of the differential bioenergetic action elicited by
EFV. Although mitochondrial parameters were additionally af-
fected when EFV was used together with DETA-NO in both cell
lines (with a signiﬁcant additive effect in superoxide production
and a decrease in Δψm), glioma cells maintained their viability,
315whereas neuroblastoma cells signiﬁcantly decreased in num-
bers/viability, compared with EFV or DETA-NO treatments
alone. As bioenergetic characteristics are different in the 2 cell
types, it seems that the synergistic effect of EFV + DETA-NO in
triggering glycolysis in glioma cells enables them to maintain
320their viability, whereas the lack of enhanced glycolysis in the
neuroblastoma cells makes them more vulnerable to the addi-
tion of a second mitotoxic stimulus.
In some of the experiments (ie, those assessing superoxide
production and cell viability), cells were co-incubated with
325the NO scavenger PTIO (2-phenyl-4,4,5,5,-tetramethylimida-
zoline-1-oxyl 3-oxide) [15] to conﬁrm that DETA-NO effects
were due to the release of NO (data not shown). When primary
cell cultures of glia and neurons were treated with EFV +
DETA-NO (Figure 5), the additive effect on the bioenergetics
330was reproduced with slight variations. DETA-NO potentiated
the enhancing effect of EFV on levels of ATP (Figure 5A) and
lactate (Figure 5B) in astrocytes. However, DETA-NO produced
a signiﬁcant drop in ATP content in primary neurons that was
potentiated in the presence of EFV, while no effect was exerted
335on lactate production. These differences between the responses
of neuroblastoma cells and primary neurons were probably due
to intrinsic metabolic differences. The experiment regarding cell
number and viability in primary cell cultures reproduced the re-
sults obtained with the immortalized cell lines, showing an ad-
340ditive effect of EFV + DETA-NO in neurons but an absence of
such an effect in astrocytes (Figure 5C).
DISCUSSION
The energetic requirements of the brain and the mechanisms by
which it adapts to metabolic challenges are matters of debate,
345and particular controversy surrounds the role played by mito-
chondria. Substantial differences have been reported between
the bioenergetics of glial cells (astrocytes, microglia, and oligo-
dendrocytes) and neurons [1, 2]. Astrocytes, the only neural cell
type with a reservoir of glycogen, are highly glycolytic [16, 17].
350Neurons are not capable of maintaining ATP levels upon mito-
chondrial insult, which is crucial for cell viability, and they are
therefore more vulnerable than glia [10]. In the present work,
we describe the effects of the antiretroviral drug EFV on the
Figure 5. Effect of efavirenz (EFV) on primary cultures of neurons and
astrocytes in the presence of exogenous nitric oxide (NO). Histograms rep-
resent data obtained in the absence (vehicle; Veh) and presence of EFV 10
µM, DETA-NO (0.3 mM in neurons and 0.5 mM in glial cells), or cotreat-
ment with DETA-NO + EFV 10 µM for 24 hours. A–C, Intracellular adeno-
sine triphosphate level (A), lactate production (B), and cell number (C).
Histograms represent cell count, determined by static cytometry (Hoechst
ﬂuorescence). Data (mean ± standard error of the mean; n = 3–5, except for
panel B [n = 8]) were expressed as the percentage of the value for untreat-
ed cells (which was considered to be 100%) and analyzed by the Student t
test. *P < .05, **P < .01, ***P < .001, compared with vehicle; ^^P < .01 and
^^^P < .001 for comparisons of EFV 10 µM to DETA-NO + EFV 10 µM;
+P < .05 and ++P < .01 for comparisons of DETA-NO to DETA-NO + EFV
10 µM.
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mitochondrial function, bioenergetics, and viability of glia and
355 neurons. We observed that it altered mitochondrial respiration,
enhanced reactive oxygen species generation, and undermined
Δψm in a concentration-dependent fashion in both cell types.
However, the implications of these effects for cell bioenergetics
and survival varied in the 2 populations. In glia, EFV activated
360 AMPK, leading to upregulated glycolysis and increased intracel-
lular ATP levels, a response not observed in neurons. These re-
sults are in line with those of early reports hinting that
inhibition of mitochondrial electron transport chain complexes
with pharmacological reagents or energetic ﬂuctuations affects
365 glia and neurons in different ways [2, 18, 19]. More recently, a
similar differential reaction to that observed in our experiments
was described when complex IV (cytochrome c oxidase) of the
mitochondrial electron transport chain was inhibited with NO
[17]. As expected, NO produced mitochondrial hyperpolariza-
370 tion in glia in the present study, whereas EFV reduced Δψm. To
our knowledge, this is ﬁrst evidence that glia and neurons re-
spond differently to mitochondrial interference by clinical con-
centrations of a widely prescribed drug.
CNS toxicity is the main side effect of EFV use [4, 20–23] and
375 is known to correlate with the drug plasma levels. The recom-
mended daily dose of EFV for adults (600 mg) usually results in
3.17–12.67 µM in plasma [24], although much higher levels,
even up to 73.6 µM, have been documented [20, 23, 25–27]. Al-
though absolute cerebrospinal ﬂuid levels of EFV differ from
380those in plasma, recent results show that protein-free levels
are similar [28].
The cellular mechanisms responsible for the EFV-related
CNS side effects are not understood, but there is evidence of
deleterious actions of the drug on neuronal metabolism, as
385manifested by a reduced activity of creatine kinase, an enzyme
involved in energy homeostasis, in different areas of the mouse
brain [29]. Furthermore, 30 µM EFV undermined cell viability
in primary cultures of rat astrocytes (24 hours), an effect related
to mitochondria-generated oxidative stress [30]. In this context,
390it is relevant that EFV has recently been shown to affect mito-
chondrial complex IV in parts of the mouse brain [7] and to in-
terfere with mitochondrial function in hepatocytes through
acute and reversible inhibition of complex I, altering cellular bi-
oenergetics and leading to mitophagy and cell death [8, 31].
395HIV-infected individuals are prone to developing an inﬂam-
matory state in the brain, and up to 50% of these patients would
eventually develop a neurological disorder [32]. Moreover,
enhanced EFV-associated toxicity has been associated with in-
creased inﬂammation in the CNS. For instance, the CNS-related
400EFV side effects are more likely to appear early after initiation of
the treatment and usually coincide with the inﬂammatory state
Figure 6. Schematic representation of the effect of efavirenz (EFV) on bioenergetics in glia and neurons. Abbreviation: AMP, adenosine monophosphate;
ATP, adenosine triphosphate; ROS, reactive oxygen species; ΔΨm, mitochondrial membrane potential.
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that accompanies HIV infection per se in treatment-naive pa-
tients [5]. There is also evidence that EFV is associated with
neurocognitive disorders in otherwise asymptomatic patients
405 [6]. Finally, although the association is not ﬂawless, there are
also indications pointing to a higher frequency of EFV-induced
CNS symptoms in conditions in which CNS neuroinﬂamma-
tion may play a role, such as some mental disorders [33] or
chemical dependency [34].
410 NO is a major inﬂammatory mediator, and its upregulation
underlies many neuropathological conditions [35]. Importantly,
there is abundant evidence that HIV enhances brain NO syn-
thesis [36, 37]. In addition, NO modulates mitochondrial respi-
ration through a reversiblyQ7 inhibiting complex IV and reacts
415 with superoxide to form the highly deleterious reactive nitrogen
species peroxynitrite. Of note, glial cells are more resistant than
neurons to excess NO. Although this characteristic was initially
thought to be a result of the robust antioxidant system of glial
cells, it has been attributed more recently to the triggering of
420 glycolysis and glucose uptake [17]. In our experiments, both
DETA-NO and EFV altered mitochondrial function in glia
and neurons, while they triggered AMPK activation and, in
turn, glycolysis only in the former cell type. Of note, augmented
ATP levels were not detected when glia were incubated with
425 DETA-NO alone, probably because of the higher ATP con-
sumption required for the maintenance and/or increase in
Δψm [11]. Importantly, the effects of this NNRTI on human
cancer cell lines were reproduced in primary cultures of rat cor-
tical neurons and astrocytes, which rules out the possibility of
430 them being speciﬁc to the cell model in question.
Because of its double action, both as a proinﬂammatory stim-
ulator and a mitochondrial modulator, NO (in the form of
DETA-NO) was used for EFV cotreatment analysis. EFV -
+ DETA-NO coexposure resulted in a clear potentiation of
435 their individual effects on mitochondrial parameters in both
neurons and glia and enhanced ATP generation and lactate pro-
duction in astrocytes. In terms of cell viability, EFV + DETA-
NO cotreatment did not augment the depletion in the number
of glial cells, but it did aggravate the damaging effect of NO on
440 neurons. Excess NO could also mediate proinﬂammatory path-
ways in the brain by triggering apoptotic cell death or oxidative/
nitrosative stress, both documented in HIV-positive patients
[36, 38]. It is therefore relevant to remember that glial cells
are an important reservoir of HIV, which may promote the ex-
445 istence of a conﬁned inﬂammatory milieu in which neurons
would be continuously under the action of NO. The relevance
of this hypothesis, speciﬁcally in the context of EFV-induced
side effects in the CNS, needs further evaluation, but, as already
mentioned, a scenario of glial cell survival and neuron dege-
450 neration with signs of mitochondrial dysfunction and severe
oxidative stress has been associated with HIV-associated neuro-
cognitive disorders [3]. Again, our data are compatible with
previous evidence that EFV exacerbates parameters associated
with inﬂammation in the CNS [39] and carries a higher risk
455of HIV-associated neurocognitive disorders than other antire-
trovirals [6].
In summary, EFV exercises a direct and speciﬁc effect on the
energetic balance and viability of neurons and glia through a
mechanism involving acute mitochondrial inhibition, and the
460effects are exacerbated under neuroinﬂammatory conditions,
such as those often present in HIV-positive patients. The cell-
speciﬁc mechanisms were obtained in vitro, and although they
cannot be directly extrapolated to the human brain, we consider
them to be of relevance in understanding the interaction be-
465tween mitochondria-targeting compounds and CNS.
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